Last reviewed · How we verify

Axiron Testosterone Topical Solution

Clarus Therapeutics, Inc. · Phase 3 active Small molecule

Axiron delivers testosterone transdermally to replace deficient testosterone levels in hypogonadal men.

Axiron delivers testosterone transdermally to replace deficient testosterone levels in hypogonadal men. Used for Testosterone replacement therapy in adult males with hypogonadism.

At a glance

Generic nameAxiron Testosterone Topical Solution
Also known asAxiron solution
SponsorClarus Therapeutics, Inc.
Drug classTestosterone replacement therapy (TRT)
TargetAndrogen receptor
ModalitySmall molecule
Therapeutic areaEndocrinology
PhasePhase 3

Mechanism of action

Axiron is a topical solution containing testosterone that is absorbed through the skin, bypassing first-pass hepatic metabolism. It restores physiological testosterone levels in men with hypogonadism, thereby improving symptoms such as low libido, erectile dysfunction, fatigue, and mood disturbances. The transdermal delivery system provides steady-state hormone levels with once-daily application.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: